Pomerantz Law Firm Initiates Class Action Against Regencell Bioscience Holdings Amid Market Controversies

In a recent development from the Pomerantz Law Firm, a class action lawsuit has been filed against Regencell Bioscience Holdings Limited, a company listed on NASDAQ as RGC. The lawsuit, filed in the United States District Court for the District of Maryland, addresses numerous alleged violations of federal securities laws. This legal action specifically represents a group comprising all individuals and entities, excluding the defendants, that acquired Regencell securities between October 28, 2024, and October 31, 2025. The lawsuit aims to recover damages sustained by these investors during this period of trading volatility.

Investors who transacted in Regencell securities within the defined class period are invited to take action and can request to be appointed as Lead Plaintiff before the June 23, 2026, deadline. A detailed copy of the complaint is accessible via the Pomerantz Law Firm's official website, where affected investors can also find information on joining the class action. For further inquiries, Danielle Peyton of Pomerantz LLP is available for discussions about the case, urging all interested parties to provide their contact details and specifics of their investment in Regencell during communications.

Regencell positions itself as a pioneering bioscience company focused on the research and commercialization of traditional Chinese medicine aimed at treating ADHD and autism spectrum disorder (ASD). These conditions are often deemed challenging to cure with existing medical approaches. The company claims that, unlike conventional treatments that merely suppress symptoms, its methodologies target the underlying causes of these neurocognitive disorders.

However, the backdrop against which Regencell operates raises several concerns. As outlined in its latest filings, Regencell is classified as a